Schmedes Anne, Hey Henrik, Larsson Iben, Christensen Morten J, Brandslund Ivan
Klinisk Biokemisk Afdeling, Sygehus Lillebælt, Vejle, Kabbeltoft 25, 7100 Vejle, Denmark.
Ugeskr Laeger. 2012 Feb 27;174(9):566-9.
Vitamin D3 (25-OHD3) analyses have increased exponentially and vitamin D deficiency (< 25 nmol/l) is common (15% of patients). The aim of the paper is to discuss reasons for unsuccessful treatment and to question the use of ergocalciferol (vitamin D2). Lack of effect of treatment can be due to: 1) too low dose, 2) incorrect analytical methods when injection treatment (vitamin D2) is used, 3) obesity, 4) seasonal variations, and 5) poor compliance. Treatment is mandatory in order to prevent osteopenia and osteoporosis. Vitamin D3 is more potent than vitamin D2. Injections with vitamin D2 should be replaced by vitamin D3.
维生素D3(25-羟基维生素D3)分析呈指数级增长,维生素D缺乏(<25 nmol/l)很常见(占患者的15%)。本文旨在讨论治疗失败的原因,并质疑麦角钙化醇(维生素D2)的使用。治疗效果不佳可能是由于:1)剂量过低;2)使用注射治疗(维生素D2)时分析方法不正确;3)肥胖;4)季节变化;5)依从性差。为预防骨质减少和骨质疏松,治疗是必要的。维生素D3比维生素D2更有效。维生素D2注射应被维生素D3取代。